International patterns of palliative care in neuro-oncology: A survey of physician members of the Asian Society for Neuro-Oncology, the European Association of Neuro-Oncology, and the Society for Neuro-Oncology

Neuro-Oncology Practice

Volumn 2, Issue 2, 2015, Pages 62-69

  Walbert, Tobias ^a   Puduvalli, Vinay K ^b   Taphoorn, Martin J B ^c,d   Taylor, Andrew R ^a   Jalali, Rakesh ^e  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MEDICAL CENTER HAAGLANDEN   (Netherlands)

^e TATA MEMORIAL HOSPITAL   (India)

Author keywords

End of life; Glioblastoma; Glioma; Hospice; Palliative care

Indexed keywords

ARTICLE; BRAIN TUMOR; CANCER PATIENT; FEMALE; HEALTH CARE SURVEY; HOSPICE CARE; HUMAN; MALE; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SOCIETY; NEUROONCOLOGY; ONCOLOGY; PALLIATIVE THERAPY; PHYSICIAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

EID: 84977878952     PISSN: 20542577     EISSN: 20542585     Source Type: Journal    
DOI: 10.1093/nop/npu037     Document Type: Article

References (29)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507.
3. Prados MD, Seiferheld W, Sandler HM, et al. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys. 2004;58(4): 1147-1152.
4. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24(18):2715-2722.
5. World Health Organization. WHO definition of palliative care. Available at http://www.who.int/cancer/palliative/definition/en/. Accessed August 8, 2014.
6. Meier DE, Brawley OW. Palliative care and the quality of life. J Clin Oncol. 2011;29(20):2750-2752.
7. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742.
8. MedlinePlus. Definition of hospice. Available at www.nlm.nih.gov/medlineplus/hospicecare.html. Accessed August 8, 2014.
9. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880-887.
10. Gaertner J, Wolf J, Hallek M, Glossmann JP, Voltz R. Standardizing integration of palliative care into comprehensive cancer therapy-a disease specific approach. Support Care Cancer. 2011;19(7): 1037-1043.
11. Sizoo EM, Pasman HR, Dirven L, et al. The end-of-life phase of high-grade glioma patients: a systematic review. Support Care Cancer. 2014;22(3):847-857.
12. Walbert T, Khan M. End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. J Neurooncol. 2014;117(2):217-224.
13. Ford E, Catt S, Chalmers A, Fallowfield L. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro Oncol. 2012;14(4):392-404.
14. Dalal S, Palla S, Hui D, et al. Association between a name change from palliative to supportive care and the timing of patient referrals at a comprehensive cancer center. Oncologist. 2011;16(1): 105-111.
15. Fadul N, Elsayem A, Palmer JL, et al. Supportive versus palliative care: what's in a name?: a survey of medical oncologists and midlevel providers at a comprehensive cancer center. Cancer. 2009;115(9): 2013-2021.
16. Vaillant B, Kuo SH, de Groot J. Emerging subspecialties in neurology: neuro-oncology: a developing subspecialty with many opportunities. Neurology. 2009;72(11):e51-e53.
17. Khosla D, Patel FD, Sharma SC. Palliative care in India: current progress and future needs. Indian J Palliat Care. 2012;18(3): 149-154.
18. Li J, Davis MP, Gamier P. Palliative medicine: barriers and developments in mainland China. Curr Oncol Rep. 2011;13(4): 290-294.
19. Lynch T, Connor S, Clark D. Mapping levels of palliative care development: a global update. J Pain Symptom Manage. 2013; 45(6):1094-1106.
20. Centeno C, Clark D, Lynch T, et al. Facts and indicators on palliative care development in 52 countries of the WHO European region: results of an EAPC Task Force. Palliat Med. 2007;21(6):463-471.
21. Koekkoek JA, Dirven L, Reijneveld JC, et al. End of life care in high-grade glioma patients in three European countries: a comparative study. J Neurooncol. 2014;120(2):303-310.
22. Carver AC, Vickrey BG, Bernat JL, Keran C, Ringel SP, Foley KM. End-of-life care: a survey of US neurologists' attitudes, behavior, and knowledge. Neurology. 1999;53(2):284-293.
23. Greer JA, Jackson VA, Meier DE, Temel JS. Early integration of palliative care services with standard oncology care for patients with advanced cancer. CA Cancer J Clin. 2013;63(5): 349-363.
24. Teunissen SC, Wesker W, Kruitwagen C, de Haes HC, Voest EE, de Graeff A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34(1): 94-104.
25. Sizoo EM, Pasman HRW, Buttolo J, et al. Decision-making in the end-of-life phase of high-grade glioma patients. Eur J Cancer. 2012;48(2):226-232.
26. Li X, Xing YF, Chen ZH, Dong M,Wu XY. Palliative care in urban areas of China. Lancet Oncol. 2013;14(9):e339.
27. Klabunde CN, Willis GB, McLeod CC, et al. Improving the quality of surveys of physicians and medical groups: a research agenda. Eval Health Prof. 2012;35(4):477-506.
28. Stockham AL, Ahluwalia M, Reddy CA, et al. Results of a questionnaire regarding practice patterns for the diagnosis and treatment of intracranial radiation necrosis after SRS. J Neurooncol. 2013;115(3): 469-475.
29. Abrey LE, Louis DN, Paleologos N, et al. Survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol. 2007;9(3):314-318.